These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17068151)

  • 1. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
    Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
    Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
    Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
    Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
    Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
    Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
    Gaikwad A; Rye CL; Devidas M; Heerema NA; Carroll AJ; Izraeli S; Plon SE; Basso G; Pession A; Rabin KR
    Br J Haematol; 2009 Mar; 144(6):930-2. PubMed ID: 19120350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
    Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
    Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
    Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
    Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
    Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2--a new player in acute lymphoblastic leukaemia.
    Mullighan CG
    Lancet; 2008 Oct; 372(9648):1448-50. PubMed ID: 18805580
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
    van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
    Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
    Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
    Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
    Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
    Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
    Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
    Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
    Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute lymphoblastic leukemia of Down Syndrome - Genetics and pathogenesis.
    Izraeli S
    Eur J Med Genet; 2016 Mar; 59(3):158-61. PubMed ID: 26631987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
    Tigay JH
    J Pediatr Oncol Nurs; 2009; 26(6):362-8. PubMed ID: 20032297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
    Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
    Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.